NeuroQure, a leader in neurodevelopmental diagnostics, today announced the launch of its groundbreaking autism spectrum disorder (ASD) screening test. This innovative solution aims to revolutionize early detection and intervention for ASD.

"We're thrilled to bring this innovative solution to families and healthcare providers," said Dr. Jane Doe, Chief Medical Officer at NeuroQure.

Key Features

• Early detection capabilities
• Non-invasive testing process
• Comprehensive results analysis
• Integration with existing healthcare systems

The new screening test utilizes advanced calcium signaling biomarkers to provide accurate and reliable results. By analyzing subtle cellular indicators, the test significantly enhances early diagnosis, allowing for timely intervention.

Availability

NeuroQure's new screening test is now available nationwide through authorized healthcare providers.